Patients experienced relief of symptoms upon discontinuation of the medication
Increased adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during neuropsychiatric drug treatment [36]
DHA, dihydroartemisinin
Nu bn thng xuyn gp tnh trng ny th thay v ung liu nhiu du c vo ban m, hy chia nh hn v ung vo bui sng v bui ti
Patients should be monitored for treatment response through serial measurements of weight, waist circumference, glycemic parameters, and lipid profiles
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 digital issues and online access to articles 118,99 per year only 9,92 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF